Event-Driven Stocks

Alkermes

ALKSNasdaq

Other · Pharmaceutical Preparations · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 5 good● 1 warningdetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue$1.48B$1.56B$1.66B$1.11B$1.17B$1.04B
Operating income$254.0M$420.6M$414.1M−$142.3M−$29.3M−$112.4M
Net income$241.7M$367.1M$355.8M−$158.3M−$48.2M−$110.9M
Total assets$2.49B$2.06B$2.14B$1.96B$2.02B$1.95B
Total liabilities$667.7M$590.6M$933.5M$920.2M$911.9M$882.7M
Equity$1.82B$1.46B$1.20B$1.04B$1.11B$1.07B
EPS (diluted)$1.43$2.17$2.10$-0.97$-0.30$-0.70
Shares out.162.6M167.1M164.4M162.0M159.2M157.8M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
17.2%
Net margin
16.4%
Return on equity
13.3%
Return on assets
9.7%
Return on capital (ROCE)
13.1%
Liabilities / assets
26.8%
Debt / equity
0.37×
Book value / share
$11.19
Revenue growth (YoY)
−5.2%
Net income growth (YoY)
−34.2%

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Altman Z″ (distress)
6.24safe
Accruals / assets
−11.2%clean
Beneish M-Score
-3.28normal
Piotroski F-Score
6/9mixed

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
67
/ 100
Profitability 100Growth 0Catalyst 33Earnings quality 100Financial strength 100

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 1 warning● 5 good
  • Revenue declined year-over-year
  • Operating margin is positive
  • Conservative leverage (liabilities < 50% of assets)
  • Positive operating cash flow
  • Clean earnings (low accruals)
  • Altman Z″ in the safe zone

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

FDA-approved drugs

openFDA · most recent
  • VIVITROLApr 13, 2006

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 202618.3M7.5-7.5%
Apr 30, 202619.8M12.6+0.4%
Apr 15, 202619.7M8.2+3.5%
Mar 31, 202619.0M5.9-7.7%
Mar 13, 202620.6M9.4+13.2%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Corporate family

Spin-offs from Alkermes (1)

From the spin-off filings we track. Follow a company to walk its own history.

Event-driven situations (1)